BioTelemetry Earnings Calls

Q4 2024 (Upcoming)
Release date Mar 19, 2025
EPS estimate -$0.180
EPS actual -
Revenue estimate -
Revenue actual -
Expected change +/- 7.47%
Q3 2024 Missed
-$0.190 (-11.76%)
Release date Nov 07, 2024
EPS estimate -$0.170
EPS actual -$0.190
EPS Surprise -11.76%
Revenue estimate -
Revenue actual -
Q2 2024 Missed
-$0.190 (-18.75%)
Release date Aug 14, 2024
EPS estimate -$0.160
EPS actual -$0.190
EPS Surprise -18.75%
Revenue estimate -
Revenue actual -
Q1 2024 Missed
-$0.170 (-13.33%)
Release date May 09, 2024
EPS estimate -$0.150
EPS actual -$0.170
EPS Surprise -13.33%
Revenue estimate -
Revenue actual -

Last 4 Quarters for BioTelemetry

Below you can see how BEAT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024 Missed
Release date May 09, 2024
Fiscal end date Mar 31, 2024
Price on release $2.01
EPS estimate -$0.150
EPS actual -$0.170
EPS surprise -13.33%
Date Price
May 03, 2024 $2.21
May 06, 2024 $2.10
May 07, 2024 $2.05
May 08, 2024 $2.09
May 09, 2024 $2.01
May 10, 2024 $1.96
May 13, 2024 $2.00
May 14, 2024 $2.06
May 15, 2024 $2.15
4 days before -9.05%
4 days after 6.97%
On release day -2.49%
Change in period -2.71%
Q2 2024 Missed
Release date Aug 14, 2024
Fiscal end date Jun 30, 2024
Price on release $2.27
EPS estimate -$0.160
EPS actual -$0.190
EPS surprise -18.75%
Date Price
Aug 08, 2024 $2.26
Aug 09, 2024 $2.20
Aug 12, 2024 $2.23
Aug 13, 2024 $2.25
Aug 14, 2024 $2.27
Aug 15, 2024 $2.31
Aug 16, 2024 $2.29
Aug 19, 2024 $2.20
Aug 20, 2024 $2.14
4 days before 0.442%
4 days after -5.73%
On release day 1.76%
Change in period -5.31%
Q3 2024 Missed
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $2.33
EPS estimate -$0.170
EPS actual -$0.190
EPS surprise -11.76%
Date Price
Nov 01, 2024 $2.49
Nov 04, 2024 $2.43
Nov 05, 2024 $2.44
Nov 06, 2024 $2.51
Nov 07, 2024 $2.33
Nov 08, 2024 $2.57
Nov 11, 2024 $2.41
Nov 12, 2024 $2.36
Nov 13, 2024 $2.31
4 days before -6.43%
4 days after -1.07%
On release day 10.30%
Change in period -7.43%
Q4 2024 (Upcoming)
Release date Mar 19, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate -$0.180
EPS actual -
Date Price
Feb 10, 2025 $2.36
Feb 11, 2025 $2.29
Feb 12, 2025 $2.24
Feb 13, 2025 $2.18
Feb 14, 2025 $2.13

BioTelemetry Earnings Call Transcript Summary of Q3 2024

  • The U.S. market for this technology is significant, with estimated addressable markets exceeding $100 billion annually.
  • The company is targeting direct patient pay initially, specifically in the concierge and preventive cardiology sectors, before expanding towards insurance reimbursement.
FDA Submission Update:
  • The 510(k) submission for FDA clearance is currently under review. HeartBeam has actively responded to FDA inquiries and remains optimistic about achieving clearance.
  • The foundational clearance will facilitate future submissions and expand product pathways.
Management Changes:
  • Rob Eno has been appointed CEO, succeeding Branislav Vajdic, who continues as the founder and leader of technical advancements.
  • This transition is aimed at leveraging Eno’s commercial expertise as the company approaches the commercialization phase.
Clinical Evidence and Recognition:
  • HeartBeam has nine peer-reviewed publications demonstrating its technology's efficacy, with over 500 patients enrolled in various studies.
  • Recent recognition includes being named a "Rising Star" at the Global Healthcare Conference and a MedTech Breakthrough Award for best new ECG technology.
Financial Overview:
  • The net loss for Q3 2024 was approximately $5 million; however, cash used in operations was lower at $3.3 million, focusing on R&D and clinical initiatives.
  • Cash balance reported at the end of Q3 was $5.8 million. Management emphasizes financial discipline and minimizing cash burn while progressing toward key milestones.
Upcoming Milestones:
  • Key value creation milestones include obtaining FDA clearance, launching an early access program, and initiating a limited commercial launch post-clearance.
  • Clinical studies presenting new data at the American Heart Association Conference are forthcoming, providing critical insights before the pivotal U.S. study aimed at FDA submission.
Investor Considerations:
  • While significant revenues are not expected in 2025, the company is positioning itself for a robust market entry and has a clear roadmap for commercialization.
  • Potential for future revenue growth hinges on the successful completion of FDA processes, clinical validations, and establishing a strategic market presence post-clearance.
Conclusion:

HeartBeam is at a pivotal point with a strong clinical foundation, innovative technology, and an evolving management team aimed at executing its go-to-market strategy. Investors should monitor upcoming FDA clearance outcomes, clinical study results, and the company’s approach to capital management closely as these will be critical for future growth and success.

BioTelemetry Earnings History

Earnings Calendar

FAQ

When is the earnings report for BEAT?
BioTelemetry (BEAT) has scheduled its earnings report for Mar 19, 2025 before the markets open.

What is the BEAT price-to-earnings (P/E) ratio?
BEAT P/E ratio as of Feb 14, 2025 (TTM) is -3.25.

What is the BEAT EPS forecast?
The forecasted EPS (Earnings Per Share) for BioTelemetry (BEAT) for the first fiscal quarter 2024 is -$0.180.

What are BioTelemetry's retained earnings?
On its balance sheet, BioTelemetry reported retained earnings of $0 for the latest quarter ending Sep 30, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT BIOTELEMETRY
BioTelemetry
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the...
GOLDEN STAR
Ticker Change Signal Date
T
TBIL
$49.90
0.0802% Feb 12
I
IBTF
$23.33
0.0429% Feb 12
SKT
$33.58
2.00% Feb 12
BSY
$46.63
1.33% Feb 11
IBN
$29.02
0.482% Feb 11

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE